Drug Therapies for Patients with IgA Nephropathy: A Network Meta-analysis of Randomized Clinical Trials

Author(s): Kannan Sridharan*, Gowri Sivaramakrishnan

Journal Name: Current Clinical Pharmacology
Continued as Current Reviews in Clinical and Experimental Pharmacology

Volume 15 , Issue 2 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Several drugs are used for treating IgA nephropathy (IgAN). We carried out a network meta-analysis evaluating these drugs.

Methods: Electronic databases were searched for appropriate randomized clinical trials carried out in patients with IgAN. The primary outcome was proteinuria remission rates and there were several other secondary outcome measures. The risk of bias was assessed. Mixed treatment comparison estimates were modelled from direct and indirect comparison estimates. Grading of the evidence for key comparisons was carried out.

Results: Fifty-seven clinical trials were included in the systematic review and 51 in the metaanalysis. Polyunsaturated fatty acids, corticosteroids/angiotensin receptor blockers (ARB), ARB, angiotensin converting enzyme inhibitors (ACEI), ARB/ACEI, corticosteroids/ACEI and hypolipidemics/ ARB were observed with significantly higher rates of proteinuria remission than the standard of care. Several benefits were observed with other drugs on the secondary outcome measures. A very low grade was observed for the interventions.

Conclusion: We observed a few interventions to perform better in the management of IgAN. The results of this study will aid in further evaluation of such drugs that may assist in saving the resources and time. However, the readers should interpret the findings with great caution as the results might change with the advent of future head-to-head clinical trials.

Keywords: Corticosteroids, immunosuppressants, angiotensin receptor blockers, angiotensin converting enzyme inhibitors, renin inhibitors, hypolipidemics.

[1]
Julian BA, Waldo FB, Rifai A, Mestecky J. IgA nephropathy, the most common glomerulonephritis worldwide. A neglected disease in the United States? Am J Med 1988; 84(1): 129-32.
[http://dx.doi.org/10.1016/0002-9343(88)90019-8] [PMID: 3337116]
[2]
Shu D, Xu F, Su Z, et al. Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case-control study. BMC Nephrol 2017; 18(1): 11.
[http://dx.doi.org/10.1186/s12882-016-0429-x] [PMID: 28061828]
[3]
Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med 2013; 368(25): 2402-14.
[http://dx.doi.org/10.1056/NEJMra1206793] [PMID: 23782179]
[4]
Lv J, Shi S, Xu D, et al. Evaluation of the Oxford Classification of IgA nephropathy: A systematic review and meta-analysis. Am J Kidney Dis 2013; 62(5): 891-9.
[http://dx.doi.org/10.1053/j.ajkd.2013.04.021] [PMID: 23820066]
[5]
Liu Y, Ma X, Zheng J, Liu X, Yan T. A systematic review and meta-analysis of kidney and pregnancy outcomes in IgA nephropathy. Am J Nephrol 2016; 44(3): 187-93.
[http://dx.doi.org/10.1159/000446354] [PMID: 27578454]
[6]
Rauen T, Eitner F, Fitzner C, et al. STOP-IgAN Investigators. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 2015; 373(23): 2225-36.
[http://dx.doi.org/10.1056/NEJMoa1415463] [PMID: 26630142]
[7]
Kawamura T. Treatment of IgA nephropathy: Corticosteroids, tonsillectomy, and mycophenolate mofetil. Contrib Nephrol 2007; 157: 37-43.
[http://dx.doi.org/10.1159/000102286] [PMID: 17495435]
[8]
Nagy J, Sági B, Máté J, Vas T, Kovács T. Considerations on the treatment of IgA nephropathy on the basis of the results of the latest studies (STOP-IgAN, TESTING, NEFIGAN) Orv Hetil 2017; 158(49): 1946-52.
[http://dx.doi.org/10.1556/650.2017.30924]] [PMID: 29199436]
[9]
Floege J, Eitner F. Current therapy for IgA nephropathy. J Am Soc Nephrol 2011; 22(10): 1785-94.
[http://dx.doi.org/10.1681/ASN.2011030221] [PMID: 21903997]
[10]
Zhou YH, Tang LG, Guo SL, et al. Steroids in the treatment of IgA nephropathy to the improvement of renal survival: A systematic review and meta-analysis. PLoS One 2011; 6(4)e18788
[http://dx.doi.org/10.1371/journal.pone.0018788] [PMID: 21533280]
[11]
Vecchio M, Bonerba B, Palmer SC, et al. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev 2015; (8): CD003965
[http://dx.doi.org/10.1002/14651858.CD003965.pub2] [PMID: 26235292]
[12]
Reid S, Cawthon PM, Craig JC, Samuels JA, Molony DA, Strippoli GF. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev 2011; (3): CD003962
[http://dx.doi.org/10.1002/14651858.CD003962.pub2] [PMID: 21412884]
[13]
Rodrigues JC, Haas M, Reich HN. IgA Nephropathy. Clin J Am Soc Nephrol 2017; 12(4): 677-86.
[http://dx.doi.org/10.2215/CJN.07420716] [PMID: 28159829]
[14]
Shim S, Yoon BH, Shin IS, Bae JM. Network meta-analysis: Application and practice using Stata. Epidemiol Health 2017; 39e2017047
[http://dx.doi.org/10.4178/epih.e2017047] [PMID: 29092392]
[15]
Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann Intern Med 2015; 162(11): 777-84.
[http://dx.doi.org/10.7326/M14-2385] [PMID: 26030634]
[16]
Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions 510 edition www.cochrane-handbook.org
[17]
Sedgwick P, Marston L. How to read a funnel plot in a meta-analysis. BMJ 2015; 351(351): h4718.
[http://dx.doi.org/10.1136/bmj.h4718] [PMID: 26377337]
[18]
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21(11): 1539-58.
[http://dx.doi.org/10.1002/sim.1186] [PMID: 12111919]
[19]
Barendregt JJ, Doi SA. MetaXL user guide http://www.epigear.com/index_files/MetaXL%20User%20Guide.pdf
[20]
Alexopoulos E, Stangou M, Pantzaki A, Kirmizis D, Memmos D. Treatment of severe IgA nephropathy with omega-3 fatty acids: the effect of a “very low dose” regimen. Ren Fail 2004; 26(4): 453-9.
[http://dx.doi.org/10.1081/JDI-200026763] [PMID: 15462115]
[21]
Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002; 13(1): 142-8.
[PMID: 11752031]
[22]
Bennett WM, Walker RG, Kincaid-Smith P. Treatment of IgA nephropathy with Eicosapentanoic Acid (EPA): a two-year prospective trial. Clin Nephrol 1989; 31(3): 128-31.
[PMID: 2539929]
[23]
Chan JC, Mahan JD, Trachtman H, et al. Vitamin E therapy in IgA nephropathy: A double-blind, placebo-controlled study. Pediatr Nephrol 2003; 18(10): 1015-9.
[http://dx.doi.org/10.1007/s00467-003-1205-2] [PMID: 12920628]
[24]
Chen X, Chen P, Cai G, et al. A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy. Zhonghua Yi Xue Za Zhi 2002; 82(12): 796-801.
[PMID: 12126522]
[25]
Chen X, Qiu Q, Tang L, et al. Effects of co-administration of urokinase and benazepril on severe IgA nephropathy. Nephrol Dial Transplant 2004; 19(4): 852-7.
[http://dx.doi.org/10.1093/ndt/gfh069] [PMID: 15031340]
[26]
Cheng G, Liu D, Margetts P, et al. Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy. Nephrology (Carlton) 2015; 20(2): 77-84.
[http://dx.doi.org/10.1111/nep.12359] [PMID: 25358874]
[27]
Coppo R, Peruzzi L, Amore A, et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 2007; 18(6): 1880-8.
[http://dx.doi.org/10.1681/ASN.2006040347] [PMID: 17513327]
[28]
Cruzado JM, Poveda R, Ibernón M, et al. Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy. Nephrol Dial Transplant 2011; 26(11): 3596-602.
[http://dx.doi.org/10.1093/ndt/gfr072] [PMID: 21393611]
[29]
Donadio JV Jr, Bergstralh EJ, Offord KP, Spencer DC, Holley KE. Mayo Nephrology Collaborative Group. A controlled trial of fish oil in IgA nephropathy. N Engl J Med 1994; 331(18): 1194-9.
[http://dx.doi.org/10.1056/NEJM199411033311804] [PMID: 7935657]
[30]
Fellström BC, Barratt J, Cook H, et al. NEFIGAN trial investigators. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): A double-blind, randomised, placebo-controlled phase 2b trial. Lancet 2017; 389(10084): 2117-27.
[http://dx.doi.org/10.1016/S0140-6736(17)30550-0] [PMID: 28363480]
[31]
Ferraro PM, Ferraccioli GF, Gambaro G, Fulignati P, Costanzi S. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: A randomized controlled trial. Nephrol Dial Transplant 2009; 24(1): 156-60.
[http://dx.doi.org/10.1093/ndt/gfn454] [PMID: 18685141]
[32]
Frascà GM, Martello M, Sestigiani E, Canova C, Vangelista A, Bonomini V. Effects of defibrotide treatment in patients with IgA nephropathy and reduced renal function. Nephrol Dial Transplant 1996; 11(2): 392-3.
[http://dx.doi.org/10.1093/oxfordjournals.ndt.a027280] [PMID: 8700366]
[33]
Frisch G, Lin J, Rosenstock J, et al. Mycophenolate Mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: A double-blind randomized controlled trial. Nephrol Dial Transplant 2005; 20(10): 2139-45.
[http://dx.doi.org/10.1093/ndt/gfh974] [PMID: 16030050]
[34]
Harmankaya O, Oztürk Y, Baştürk T, Obek A, Kiliçarslan I. Efficacy of immunosuppressive therapy in IgA nephropathy presenting with isolated hematuria. Int Urol Nephrol 2002; 33(1): 167-71.
[http://dx.doi.org/10.1023/A:1014424723466] [PMID: 12090325]
[35]
Hirai K, Ookawara S, Kitano T, et al. Efficacy and safety of adding mizoribine to standard treatment in patients with immunoglobulin A nephropathy: A randomized controlled trial. Kidney Res Clin Pract 2017; 36(2): 159-66.
[http://dx.doi.org/10.23876/j.krcp.2017.36.2.159] [PMID: 28680823]
[36]
Hogg RJ, Lee J, Nardelli N, et al. Southwest Pediatric Nephrology Study Group. Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: Report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol 2006; 1(3): 467-74.
[http://dx.doi.org/10.2215/CJN.01020905] [PMID: 17699247]
[37]
Hogg RJ, Bay RC, Jennette JC, et al. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy. Am J Kidney Dis 2015; 66(5): 783-91.
[http://dx.doi.org/10.1053/j.ajkd.2015.06.013] [PMID: 26209543]
[38]
Horita Y, Tadokoro M, Taura K, et al. Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy. Hypertens Res 2004; 27(12): 963-70.
[http://dx.doi.org/10.1291/hypres.27.963] [PMID: 15894837]
[39]
Horita Y, Tadokoro M, Taura K, et al. Prednisolone co-administered with losartan confers renoprotection in patients with IgA nephropathy. Ren Fail 2007; 29(4): 441-6.
[http://dx.doi.org/10.1080/08860220701260511] [PMID: 17497466]
[40]
Hou JH, Le WB, Chen N, et al. Mycophenolate mofetil com-bined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: A randomized controlled trial. Am J Kidney Dis 2017; 69(6): 788-95.
[http://dx.doi.org/10.1053/j.ajkd.2016.11.027] [PMID: 28215945]
[41]
Li PK, Leung CB, Chow KM, et al. HKVIN Study Group. Hong Kong study using Valsartan in IgA Nephropathy (HKVIN): A double-blind, randomized, placebo-controlled study. Am J Kidney Dis 2006; 47(5): 751-60.
[http://dx.doi.org/10.1053/j.ajkd.2006.01.017] [PMID: 16632013]
[42]
Kanno Y, Witt M, Okada H, et al. A comparison of corticosteroid and warfarin therapy in IgA nephropathy with crescent formation: Preliminary trial. Clin Exp Nephrol 2003; 7(1): 48-51.
[http://dx.doi.org/10.1007/s101570300006] [PMID: 14586743]
[43]
Katafuchi R, Ikeda K, Mizumasa T, et al. Controlled, prospective trial of steroid treatment in IgA nephropathy: A limitation of low-dose prednisolone therapy. Am J Kidney Dis 2003; 41(5): 972-83.
[http://dx.doi.org/10.1016/S0272-6386(03)00194-X] [PMID: 12722031]
[44]
Kawamura T, Yoshimura M, Miyazaki Y, et al. Special IgA Nephropathy Study Group. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant 2014; 29(8): 1546-53.
[http://dx.doi.org/10.1093/ndt/gfu020] [PMID: 24596084]
[45]
Kawasaki Y, Takano K, Suyama K, et al. Efficacy of tonsillectomy pulse therapy versus multiple-drug therapy for IgA nephropathy. Pediatr Nephrol 2006; 21(11): 1701-6.
[http://dx.doi.org/10.1007/s00467-006-0272-6] [PMID: 16932894]
[46]
Kim YC, Chin HJ, Koo HS, Kim S. Tacrolimus decreases albuminuria in patients with IgA nephropathy and normal blood pressure: A double-blind randomized controlled trial of efficacy of tacrolimus on IgA nephropathy. PLoS One 2013; 8(8)e71545
[http://dx.doi.org/10.1371/journal.pone.0071545] [PMID: 23977072]
[47]
Kloke HJ, Wetzels JF, Koene RA, Huysmans FT. Effects of low-dose nifedipine on urinary protein excretion rate in patients with renal disease. Nephrol Dial Transplant 1998; 13(3): 646-50.
[http://dx.doi.org/10.1093/ndt/13.3.646] [PMID: 9550641]
[48]
Lafayette RA, Canetta PA, Rovin BH, et al. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol 2017; 28(4): 1306-13.
[http://dx.doi.org/10.1681/ASN.2016060640] [PMID: 27821627]
[49]
Lai KN, Lai FM, Ho CP, Chan KW. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: A long-term controlled trial. Clin Nephrol 1986; 26(4): 174-80.
[PMID: 3536231]
[50]
Lee S-H, Shim JJ, Lee SH, et al. Effect of combined treatment of steroid and angiotensin II receptor blocker in proteinuric IgA nepropathy. Korean Journal of Nephrology 2003; 22: 539-45.
[51]
Liu X, Wang H, Chen W, et al. Comparison of therapeutic effect of higher-dose valsartan combined with higher dose of lotensin for IgA nephropathy. Journal of Xian Jiaotong Uni-versity 2007; 28: 437-40.
[52]
Liu H, Xu X, Fang Y, et al. Comparison of glucocorticoids alone and combined with cyclosporine a in patients with IgA nephropathy: A prospective randomized controlled trial. Intern Med 2014; 53(7): 675-81.
[http://dx.doi.org/10.2169/internalmedicine.53.1136] [PMID: 24694475]
[53]
Liu LJ, Lv JC, Shi SF, Chen YQ, Zhang H, Wang HY. Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: A randomized controlled trial. Am J Kidney Dis 2012; 59(1): 67-74.
[http://dx.doi.org/10.1053/j.ajkd.2011.09.014] [PMID: 22019331]
[54]
Lou T, Wang C, Chen Z, et al. Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy. Nephrology (Carlton) 2006; 11(2): 113-6.
[http://dx.doi.org/10.1111/j.1440-1797.2006.00547.x] [PMID: 16669971]
[55]
Lv J, Zhang H, Chen Y, et al. Combination therapy of prednisone and ACE inhibitor vs. ACE-inhibitor therapy alone in patients with IgA nephropathy: A randomized controlled trial. Am J Kidney Dis 2009; 53(1): 26-32.
[http://dx.doi.org/10.1053/j.ajkd.2008.07.029] [PMID: 18930568]
[56]
Maes BD, Oyen R, Claes K, et al. Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study. Kidney Int 2004; 65(5): 1842-9.
[http://dx.doi.org/10.1111/j.1523-1755.2004.00588.x] [PMID: 15086925]
[57]
Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 2009; 24(12): 3694-701.
[http://dx.doi.org/10.1093/ndt/gfp356] [PMID: 19628647]
[58]
Masutani K, Tsuchimoto A, Yamada T, et al. West Japan Study Group for Therapy of IgA Nephropathy Investigators. Comparison of steroid-pulse therapy and combined with mizoribine in IgA nephropathy: A randomized controlled trial. Clin Exp Nephrol 2016; 20(6): 896-903.
[http://dx.doi.org/10.1007/s10157-016-1226-3] [PMID: 26758039]
[59]
Min L, Wang Q, Cao L, et al. Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy. Oncotarget 2017; 8(29): 48375-84.
[http://dx.doi.org/10.18632/oncotarget.16468] [PMID: 28415636]
[60]
Perico N, Remuzzi A, Sangalli F, et al. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. J Am Soc Nephrol 1998; 9(12): 2308-17.
[PMID: 9848785]
[61]
Pettersson EE, Rekola S, Berglund L, et al. Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: A prospective, double-blind, randomized study. Clin Nephrol 1994; 41(4): 183-90.
[PMID: 8026109]
[62]
Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy: A randomised controlled trial. Lancet 1999; 353(9156): 883-7.
[http://dx.doi.org/10.1016/S0140-6736(98)03563-6] [PMID: 10093981]
[63]
Pozzi C, Andrulli S, Pani A, et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol 2010; 21(10): 1783-90.
[http://dx.doi.org/10.1681/ASN.2010010117] [PMID: 20634300]
[64]
Praga M, Gutiérrez E, González E, Morales E, Hernández E. Treatment of IgA nephropathy with ACE inhibitors: A randomized and controlled trial. J Am Soc Nephrol 2003; 14(6): 1578-83.
[http://dx.doi.org/10.1097/01.ASN.0000068460.37369.DC] [PMID: 12761258]
[65]
Sato M, Takayama K, Kojima H, Koshikawa S. Sodium cromoglycate therapy in IgA nephropathy: A preliminary short-term trial. Am J Kidney Dis 1990; 15(2): 141-6.
[http://dx.doi.org/10.1016/S0272-6386(12)80511-7] [PMID: 2105638]
[66]
Shimizu A, Takei T, Uchida K, Tsuchiya K, Nitta K. Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy. Hypertens Res 2008; 31(9): 1711-7.
[http://dx.doi.org/10.1291/hypres.31.1711] [PMID: 18971549]
[67]
Stangou M, Ekonomidou D, Giamalis P, et al. Steroids and azathioprine in the treatment of IgA nephropathy. Clin Exp Nephrol 2011; 15(3): 373-80.
[http://dx.doi.org/10.1007/s10157-011-0415-3] [PMID: 21301920]
[68]
Szeto CC, Kwan BC, Chow KM, Leung CB, Li PK. The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy-A randomized cross-over study. PLoS One 2013; 8(5)e62736
[http://dx.doi.org/10.1371/journal.pone.0062736] [PMID: 23675422]
[69]
Tang S, Leung JC, Chan LY, et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 2005; 68(2): 802-12.
[http://dx.doi.org/10.1111/j.1523-1755.2005.00460.x] [PMID: 16014059]
[70]
Walker RG, Yu SH, Owen JE, Kincaid-Smith P. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial. Clin Nephrol 1990; 34(3): 103-7.
[PMID: 2225560]
[71]
Woo KT, Chan CM, Tan HK, et al. Beneficial effects of high-dose losartan in IgA nephritis. Clin Nephrol 2009; 71(6): 617-24.
[http://dx.doi.org/10.5414/CNP71617] [PMID: 19473629]
[72]
Wu J, Duan SW, Sun XF, et al. Efficacy of leflunomide, telmisartan, and clopidogrel for immunoglobulin A nephropa-thy: A randomized controlled trial. Chin Med J (Engl) 2016; 129(16): 1894-903.
[http://dx.doi.org/10.4103/0366-6999.187848] [PMID: 27503012]
[73]
Xie Y, Huang S, Wang L, et al. Efficacy and safety of mizoribine combined with losartan in the treatment of IgA nephropathy: A multicenter, randomized, controlled study. Am J Med Sci 2011; 341(5): 367-72.
[http://dx.doi.org/10.1097/MAJ.0b013e318207e02d] [PMID: 21293249]
[74]
Ye Z, Zhang L, Xu L, et al. Probucol combined with valsartan in immunoglobulin A nephropathy: A multi-centre, open labelled, randomized controlled study. Nephrology (Carlton) 2014; 19(1): 40-6.
[http://dx.doi.org/10.1111/nep.12177] [PMID: 24191893]
[75]
Yoshikawa N, Ito H, Sakai T, et al. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. J Am Soc Nephrol 1999; 10(1): 101-9.
[PMID: 9890315]
[76]
Yoshikawa N, Honda M, Iijima K, et al. Japanese Pediatric IgA Nephropathy Treatment Study Group. Steroid treatment for severe childhood IgA nephropathy: A randomized, controlled trial. Clin J Am Soc Nephrol 2006; 1(3): 511-7.
[http://dx.doi.org/10.2215/CJN.01120905] [PMID: 17699253]
[77]
Yang P, Zou H, Xiao B, Xu G. Comparative efficacy and safe-ty of therapies in IgA nephropathy. A network meta-analysis of randomized controlled trials. Kidney Int Rep 2018; 3(4): 794-803.
[http://dx.doi.org/10.1016/j.ekir.2018.03.006] [PMID: 29989013]
[78]
Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines-Application to the individual patient. Kidney Int 2012; 82(8): 840-56.
[http://dx.doi.org/10.1038/ki.2012.280] [PMID: 22895519]
[79]
Ohashi N, Urushihara M, Kobori H. Activated intrarenal reactive oxygen species and renin angiotensin system in IgA nephropathy. Minerva Urol Nefrol 2009; 61(1): 55-66.
[PMID: 19417726]
[80]
Lv J, Xu D, Perkovic V, et al. TESTING Study Group. Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol 2012; 23(6): 1108-16.
[http://dx.doi.org/10.1681/ASN.2011111112] [PMID: 22539830]
[81]
Zhang Y, Luo J, Hu B, Ma T. Efficacy and safety of tacrolimus combined with glucocorticoid treatment for IgA nephropathy: A meta-analysis. J Int Med Res 2018; 46(8): 3236-50.
[http://dx.doi.org/10.1177/0300060518776566] [PMID: 29882450]
[82]
Kidney Disease Improving Global Outcomes clinical practice guidelines for glomerulonephritis http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO%20GN%20Suppl%20Online%20Tables%20May%202012.pdf [Accessed on 27th November 2018]..
[83]
Jin SY, Choi IJ. The effect of sodium cromoglycate on the induction of experimental IgA nephropathy. Yonsei Med J 1990; 31(1): 33-48.
[http://dx.doi.org/10.3349/ymj.1990.31.1.33] [PMID: 2111960]
[84]
Bazzi C, Sinico RA, Petrini C, et al. Low doses of drugs able to alter intestinal mucosal permeability to food antigens (5-aminosalicylic acid and sodium cromoglycate) do not reduce proteinuria in patients with IgA nephropathy: A preliminary noncontrolled trial. Nephron 1992; 61(2): 192-5.
[http://dx.doi.org/10.1159/000186870] [PMID: 1630544]
[85]
Coppo R. Corticosteroids in IgA nephropathy: Lessons from recent studies. J Am Soc Nephrol 2017; 28(1): 25-33.
[http://dx.doi.org/10.1681/ASN.2016060647] [PMID: 27671778]
[86]
Lai KN, Chan LY, Tang SC, et al. Mesangial expression of angiotensin II receptor in IgA nephropathy and its regulation by polymeric IgA1. Kidney Int 2004; 66(4): 1403-16.
[http://dx.doi.org/10.1111/j.1523-1755.2004.00874.x] [PMID: 15458433]
[87]
Jafar TH, Stark PC, Schmid CH, et al. AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. Ann Intern Med 2003; 139(4): 244-52.
[http://dx.doi.org/10.7326/0003-4819-139-4-200308190-00006] [PMID: 12965979]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 2
Year: 2020
Published on: 13 October, 2020
Page: [132 - 144]
Pages: 13
DOI: 10.2174/1574884715666191223103914
Price: $65

Article Metrics

PDF: 34
HTML: 2